Skip to main content
Journal cover image

Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial).

Publication ,  Journal Article
Kandzari, DE; Granger, CB; Simoons, ML; White, HD; Simes, J; Mahaffey, KW; Gore, J; Weaver, WD; Longstreth, WT; Stebbins, A; Lee, KL ...
Published in: Am J Cardiol
February 15, 2004

Of 592 patients in the Global Utilization of Streptokinase and tPA for Occluded Arteries-I trial who had a stroke during initial hospitalization, the risk for intracranial hemorrhage was significantly greater in those with recent facial or head trauma (odds ratio 13.0, 95% confidence interval 3.4 to 85.5); dementia was additionally associated with an increased risk for intracranial hemorrhage (odds ratio 3.4, 95% confidence interval 1.2 to 10.2). Because facial or head trauma may greatly influence treatment decisions, this risk factor should be incorporated into models designed to estimate the risks and benefits of fibrinolytic therapy.

Duke Scholars

Published In

Am J Cardiol

DOI

ISSN

0002-9149

Publication Date

February 15, 2004

Volume

93

Issue

4

Start / End Page

458 / 461

Location

United States

Related Subject Headings

  • Tissue Plasminogen Activator
  • Thrombolytic Therapy
  • Stroke
  • Streptokinase
  • Risk Factors
  • Prospective Studies
  • Odds Ratio
  • Myocardial Infarction
  • Middle Aged
  • Male
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kandzari, D. E., Granger, C. B., Simoons, M. L., White, H. D., Simes, J., Mahaffey, K. W., … Global Utilization of Streptokinase and tPA for Occluded Arteries-I Investigators. (2004). Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial). Am J Cardiol, 93(4), 458–461. https://doi.org/10.1016/j.amjcard.2003.10.043
Kandzari, David E., Christopher B. Granger, Maarten L. Simoons, Harvey D. White, John Simes, Kenneth W. Mahaffey, Joel Gore, et al. “Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial).Am J Cardiol 93, no. 4 (February 15, 2004): 458–61. https://doi.org/10.1016/j.amjcard.2003.10.043.
Kandzari DE, Granger CB, Simoons ML, White HD, Simes J, Mahaffey KW, et al. Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial). Am J Cardiol. 2004 Feb 15;93(4):458–61.
Kandzari, David E., et al. “Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial).Am J Cardiol, vol. 93, no. 4, Feb. 2004, pp. 458–61. Pubmed, doi:10.1016/j.amjcard.2003.10.043.
Kandzari DE, Granger CB, Simoons ML, White HD, Simes J, Mahaffey KW, Gore J, Weaver WD, Longstreth WT, Stebbins A, Lee KL, Califf RM, Topol EJ, Global Utilization of Streptokinase and tPA for Occluded Arteries-I Investigators. Risk factors for intracranial hemorrhage and nonhemorrhagic stroke after fibrinolytic therapy (from the GUSTO-i trial). Am J Cardiol. 2004 Feb 15;93(4):458–461.
Journal cover image

Published In

Am J Cardiol

DOI

ISSN

0002-9149

Publication Date

February 15, 2004

Volume

93

Issue

4

Start / End Page

458 / 461

Location

United States

Related Subject Headings

  • Tissue Plasminogen Activator
  • Thrombolytic Therapy
  • Stroke
  • Streptokinase
  • Risk Factors
  • Prospective Studies
  • Odds Ratio
  • Myocardial Infarction
  • Middle Aged
  • Male